PCSK9 and coronary artery disorder: With the expanding prevalence of CAD and the increasingly widespread use of PCSK9 inhibitors (e.g., Evolocumab and Alirocumab) to reduce cardiovascular risk, accurate assessment of LDL-C levels is becoming more crucial for the secondary prevention of cardiovascular disease [13,14].